Hemangioma natural history, complications and prognosis: Difference between revisions
Jump to navigation
Jump to search
Nawal Muazam (talk | contribs) No edit summary |
Nawal Muazam (talk | contribs) No edit summary |
||
| Line 3: | Line 3: | ||
{{CMG}};{{AE}}{{NM}} | {{CMG}};{{AE}}{{NM}} | ||
==Overview== | ==Overview== | ||
Common complications of hemangioma include ischemia, necrosis, ulceration, and bleeding.<ref name="RichterFriedman2012">{{cite journal|last1=Richter|first1=Gresham T.|last2=Friedman|first2=Adva B.|title=Hemangiomas and Vascular Malformations: Current Theory and Management|journal=International Journal of Pediatrics|volume=2012|year=2012|pages=1–10|issn=1687-9740|doi=10.1155/2012/645678}}</ref> | |||
Common complications of hemangioma include [[ischemia]], [[necrosis]], [[ulceration]], and [[bleeding]].<ref name="RichterFriedman2012">{{cite journal|last1=Richter|first1=Gresham T.|last2=Friedman|first2=Adva B.|title=Hemangiomas and Vascular Malformations: Current Theory and Management|journal=International Journal of Pediatrics|volume=2012|year=2012|pages=1–10|issn=1687-9740|doi=10.1155/2012/645678}}</ref> | |||
==Natural history== | ==Natural history== | ||
*In brief, hemangiomas are vascular tumors that are rarely apparent at birth, grow rapidly during the first six months of life, involute with time and do not necessarily infiltrate but can sometimes be destructive.<ref name="RichterFriedman2012">{{cite journal|last1=Richter|first1=Gresham T.|last2=Friedman|first2=Adva B.|title=Hemangiomas and Vascular Malformations: Current Theory and Management|journal=International Journal of Pediatrics|volume=2012|year=2012|pages=1–10|issn=1687-9740|doi=10.1155/2012/645678}}</ref> | *In brief, hemangiomas are vascular tumors that are rarely apparent at birth, grow rapidly during the first six months of life, involute with time and do not necessarily infiltrate but can sometimes be destructive.<ref name="RichterFriedman2012">{{cite journal|last1=Richter|first1=Gresham T.|last2=Friedman|first2=Adva B.|title=Hemangiomas and Vascular Malformations: Current Theory and Management|journal=International Journal of Pediatrics|volume=2012|year=2012|pages=1–10|issn=1687-9740|doi=10.1155/2012/645678}}</ref> | ||
| Line 12: | Line 13: | ||
===Proliferation phase=== | ===Proliferation phase=== | ||
*In most hemangiomas, eighty percent of proliferation occurs by three months of life but may last longer.<ref name="RichterFriedman2012">{{cite journal|last1=Richter|first1=Gresham T.|last2=Friedman|first2=Adva B.|title=Hemangiomas and Vascular Malformations: Current Theory and Management|journal=International Journal of Pediatrics|volume=2012|year=2012|pages=1–10|issn=1687-9740|doi=10.1155/2012/645678}}</ref> | *In most hemangiomas, eighty percent of proliferation occurs by three months of life but may last longer.<ref name="RichterFriedman2012">{{cite journal|last1=Richter|first1=Gresham T.|last2=Friedman|first2=Adva B.|title=Hemangiomas and Vascular Malformations: Current Theory and Management|journal=International Journal of Pediatrics|volume=2012|year=2012|pages=1–10|issn=1687-9740|doi=10.1155/2012/645678}}</ref> | ||
*During proliferation, rapid growth can lead to exhaustion of blood supply with resulting ischemia, necrosis, ulceration, and bleeding. | *During proliferation, rapid growth can lead to exhaustion of blood supply with resulting ischemia, necrosis, ulceration, and bleeding. | ||
===Quiescence phase=== | ===Quiescence phase=== | ||
*Following proliferation, hemangiomas enter a slower or no growth phase, known as quiescence.<ref name="RichterFriedman2012">{{cite journal|last1=Richter|first1=Gresham T.|last2=Friedman|first2=Adva B.|title=Hemangiomas and Vascular Malformations: Current Theory and Management|journal=International Journal of Pediatrics|volume=2012|year=2012|pages=1–10|issn=1687-9740|doi=10.1155/2012/645678}}</ref> | *Following proliferation, hemangiomas enter a slower or no growth phase, known as quiescence.<ref name="RichterFriedman2012">{{cite journal|last1=Richter|first1=Gresham T.|last2=Friedman|first2=Adva B.|title=Hemangiomas and Vascular Malformations: Current Theory and Management|journal=International Journal of Pediatrics|volume=2012|year=2012|pages=1–10|issn=1687-9740|doi=10.1155/2012/645678}}</ref> | ||
*This phase typically lasts from nine to twelve months of age. | *This phase typically lasts from nine to twelve months of age. | ||
===Involution phase=== | ===Involution phase=== | ||
*The final and unique phase of the hemangioma lifecycle is involution.<ref name="RichterFriedman2012">{{cite journal|last1=Richter|first1=Gresham T.|last2=Friedman|first2=Adva B.|title=Hemangiomas and Vascular Malformations: Current Theory and Management|journal=International Journal of Pediatrics|volume=2012|year=2012|pages=1–10|issn=1687-9740|doi=10.1155/2012/645678}}</ref> | *The final and unique phase of the hemangioma lifecycle is involution.<ref name="RichterFriedman2012">{{cite journal|last1=Richter|first1=Gresham T.|last2=Friedman|first2=Adva B.|title=Hemangiomas and Vascular Malformations: Current Theory and Management|journal=International Journal of Pediatrics|volume=2012|year=2012|pages=1–10|issn=1687-9740|doi=10.1155/2012/645678}}</ref> | ||
*This phase is marked by graying of the overlying skin and shrinking of the deeper components. | *This phase is marked by graying of the overlying skin and shrinking of the deeper components. | ||
*At the final stages of involution, a fibrofatty protuberance may remain. | *At the final stages of involution, a fibrofatty protuberance may remain. | ||
==Complications== | ==Complications== | ||
Rapid growth of hemangiomas can lead to exhaustion of blood supply with resulting:<ref name="RichterFriedman2012">{{cite journal|last1=Richter|first1=Gresham T.|last2=Friedman|first2=Adva B.|title=Hemangiomas and Vascular Malformations: Current Theory and Management|journal=International Journal of Pediatrics|volume=2012|year=2012|pages=1–10|issn=1687-9740|doi=10.1155/2012/645678}}</ref> | Rapid growth of hemangiomas can lead to exhaustion of blood supply with resulting:<ref name="RichterFriedman2012">{{cite journal|last1=Richter|first1=Gresham T.|last2=Friedman|first2=Adva B.|title=Hemangiomas and Vascular Malformations: Current Theory and Management|journal=International Journal of Pediatrics|volume=2012|year=2012|pages=1–10|issn=1687-9740|doi=10.1155/2012/645678}}</ref> | ||
*Ischemia | *[[Ischemia]] | ||
*Necrosis | *[[Necrosis]] | ||
*Ulceration | *[[Ulceration]] | ||
*Bleeding | *[[Bleeding]] | ||
===Ophthalmic complications=== | ===Ophthalmic complications=== | ||
Common complications of infantile hemangioma include:<ref name="CallahanYoon2012">{{cite journal|last1=Callahan|first1=Alison B.|last2=Yoon|first2=Michael K.|title=Infantile hemangiomas: A review|journal=Saudi Journal of Ophthalmology|volume=26|issue=3|year=2012|pages=283–291|issn=13194534|doi=10.1016/j.sjopt.2012.05.004}}</ref> | Common complications of infantile hemangioma include:<ref name="CallahanYoon2012">{{cite journal|last1=Callahan|first1=Alison B.|last2=Yoon|first2=Michael K.|title=Infantile hemangiomas: A review|journal=Saudi Journal of Ophthalmology|volume=26|issue=3|year=2012|pages=283–291|issn=13194534|doi=10.1016/j.sjopt.2012.05.004}}</ref> | ||
*[[Amblyopia]] | |||
*[[Strabismus]] | |||
*[[Proptosis]] | |||
*Exposure keratopathy | |||
*[[Optic neuropathy|Compressive optic neuropathy]] | |||
==Prognosis== | ==Prognosis== | ||
==References== | ==References== | ||
Revision as of 15:29, 17 November 2015
|
Hemangioma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Hemangioma natural history, complications and prognosis On the Web |
|
American Roentgen Ray Society Images of Hemangioma natural history, complications and prognosis |
|
FDA on Hemangioma natural history, complications and prognosis |
|
CDC on Hemangioma natural history, complications and prognosis |
|
Hemangioma natural history, complications and prognosis in the news |
|
Blogs on Hemangioma natural history, complications and prognosis |
|
Risk calculators and risk factors for Hemangioma natural history, complications and prognosis |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: Nawal Muazam M.D.[2]
Overview
Common complications of hemangioma include ischemia, necrosis, ulceration, and bleeding.[1]
Natural history
- In brief, hemangiomas are vascular tumors that are rarely apparent at birth, grow rapidly during the first six months of life, involute with time and do not necessarily infiltrate but can sometimes be destructive.[1]
- Hemangiomas follow a predictable course with three distinct developmental phases:[1]
- Proliferation phase
- Quiescence phase
- Involution phase
Proliferation phase
- In most hemangiomas, eighty percent of proliferation occurs by three months of life but may last longer.[1]
- During proliferation, rapid growth can lead to exhaustion of blood supply with resulting ischemia, necrosis, ulceration, and bleeding.
Quiescence phase
- Following proliferation, hemangiomas enter a slower or no growth phase, known as quiescence.[1]
- This phase typically lasts from nine to twelve months of age.
Involution phase
- The final and unique phase of the hemangioma lifecycle is involution.[1]
- This phase is marked by graying of the overlying skin and shrinking of the deeper components.
- At the final stages of involution, a fibrofatty protuberance may remain.
Complications
Rapid growth of hemangiomas can lead to exhaustion of blood supply with resulting:[1]
Ophthalmic complications
Common complications of infantile hemangioma include:[2]
- Amblyopia
- Strabismus
- Proptosis
- Exposure keratopathy
- Compressive optic neuropathy
Prognosis
References
- ↑ 1.0 1.1 1.2 1.3 1.4 1.5 1.6 Richter, Gresham T.; Friedman, Adva B. (2012). "Hemangiomas and Vascular Malformations: Current Theory and Management". International Journal of Pediatrics. 2012: 1–10. doi:10.1155/2012/645678. ISSN 1687-9740.
- ↑ Callahan, Alison B.; Yoon, Michael K. (2012). "Infantile hemangiomas: A review". Saudi Journal of Ophthalmology. 26 (3): 283–291. doi:10.1016/j.sjopt.2012.05.004. ISSN 1319-4534.